ArticleEmerging infectious diseases2022
National Monkeypox Surveillance, Central African Republic, 2001-2021.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mpox vaccine acceptance and its predictors among people who have risky sexual practices: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.The Lancet. Global health · 2024Pooled it
- Treatment of mpox with tecovirimat under expanded access use in the Central African Republic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.Dermatology (Basel, Switzerland) · 2026Review
- Treatment of Severe Ocular Mpox with Cidofovir and Tecovirimat.Emerging infectious diseases · 2026Article
- Epidemiology, clinical features, and outcomes of Mpox in children and adolescents in Uganda, August 2024-January 2025.IJID regions · 2026Article
- Weaknesses and strengths in the emergency response and management of the first mpox case in The Gambia.Journal of public health in Africa · 2026Article
- Early epidemiologic and genomic insights from Sierra Leone's first mpox cases, 2025.The Pan African medical journal · 2026Article
- Mpox surveillance in endemic regions: a scoping review of trends, challenges, and recommendations.BMC infectious diseases · 2025Article
- Global transmission characteristics of mpox outbreaks: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Mpox and oral health among children in Africa.Frontiers in oral health · 2025Article
- Strengthening Africa's resilience to Mpox: Preparedness and response initiatives of the Pasteur network.Journal of public health in Africa · 2025Article
- The Peculiar Emergence of Mpox (Monkeypox): Directions for the Search for the Natural Reservoir and Vaccination Strategies.Vaccines · 2024Article
- Presumed Transmission of 2 Distinct Monkeypox Virus Variants from Central African Republic to Democratic Republic of the Congo.Emerging infectious diseases · 2024Article
- Mpox virus infection in women and outbreak sex disparities: A Systematic Review and Meta-analysis.Communications medicine · 2024Article
- Evaluation of the mpox surveillance system in Cameroon from 2018 to 2022: a laboratory cross-sectional study.BMC infectious diseases · 2024Article
- Seasonal Patterns of Mpox Index Cases, Africa, 1970-2021.Emerging infectious diseases · 2024Article
- Concurrent Clade I and Clade II Monkeypox Virus Circulation, Cameroon, 1979-2022.Emerging infectious diseases · 2024Review
- Role of vaccination in patients with human monkeypox virus and its cardiovascular manifestations.Annals of medicine and surgery (2012) · 2024Review
- Strengthening Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global spread.Science in One Health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed monkeypox disease surveillance in Central African Republic (CAR) during 2001-2021. Surveillance data show 95 suspected outbreaks, 40 of which were confirmed as monkeypox, comprising 99 confirmed and 61 suspected monkeypox cases. After 2018, CAR's annual rate of confirmed outbreaks increased, and 65% of outbreaks occurred in 2 forested regions bordering the Democratic Republic of the Congo. The median patient age for confirmed cases was 15.5 years. The overall case-fatality ratio was 7.5% (12/160) for confirmed and suspected cases, 9.6% (8/83) for children <16 years of age. Decreasing cross-protective immunity from smallpox vaccination and recent ecologic alterations likely contribute to increased monkeypox outbreaks in Central Africa. High fatality rates associated with monkeypox virus clade I also are a local and international concern. Ongoing investigations of zoonotic sources and environmental changes that increase human exposure could inform practices to prevent monkeypox expansion into local communities and beyond endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.